相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Design, synthesis and evaluation of anticancer activity of new pyrazoline derivatives by down-regulation of VEGF: Molecular docking and apoptosis inducing activity
Rasha A. Hassan et al.
BIOORGANIC CHEMISTRY (2022)
Synthesis and biological evaluation of halogenated phenoxychalcones and their corresponding pyrazolines as cytotoxic agents in human breast cancer
Peter A. Halim et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2022)
Novel antiproliferative agents bearing substituted thieno[2,3-d]pyrimidine scaffold as dual VEGFR-2 and BRAF kinases inhibitors and apoptosis inducers; design, synthesis and molecular docking
Rasha A. Hassan et al.
BIOORGANIC CHEMISTRY (2022)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Novel thienopyrimidine-aminothiazole hybrids: Design, synthesis, antimicrobial screening, anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis and VEGFR-2 inhibition
Yara El-Dash et al.
BIOORGANIC CHEMISTRY (2021)
Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020
Shaoyuan Lei et al.
CANCER COMMUNICATIONS (2021)
Design and synthesis of novel quinazolinones conjugated ibuprofen, indole acetamide, or thioacetohydrazide as selective COX-2 inhibitors: anti-inflammatory, analgesic and anticancer activities
Asmaa Sakr et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2021)
Divergent 2-Chloroquinazolin-4(3H)-one Rearrangement: Twisted-Cyclic Guanidine Formation or Ring-Fused N-Acylguanidines via a Domino Process
Gang Yan et al.
CHEMISTRY-A EUROPEAN JOURNAL (2020)
Design, synthesis and antiproliferative evaluation of new tricyclic fused thiazolopyrimidines targeting topoisomerase II: Molecular docking and apoptosis inducing activity
Mohamed T. M. Nemr et al.
BIOORGANIC CHEMISTRY (2020)
Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
Youjin Kim et al.
CANCER RESEARCH AND TREATMENT (2019)
Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis
Mai Maher et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2019)
Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?
Tri Le et al.
CANCERS (2019)
Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials
Amaia Eleonora Maennling et al.
CANCERS (2019)
Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology
Anna Pellat et al.
HEPATOLOGY (2018)
Molecular targeted therapy: Treating cancer with specificity
Yeuan Ting Lee et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
Third generation EGFR TKIs: current data and future directions
Chee-Seng Tan et al.
MOLECULAR CANCER (2018)
Epidermal growth factor receptor based active targeting: a paradigm shift towards advance tumor therapy
Md. Habban Akhter et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2018)
Epidermal growth factor receptor: Structure-function informing the design of anticancer therapeutics
Ruth A. Mitchell et al.
EXPERIMENTAL CELL RESEARCH (2018)
Cell cycle proliferation decisions: the impact of single cell analyses
Jacob P. Matson et al.
FEBS JOURNAL (2017)
Identification of potent cholecystokinin-B receptor antagonists: synthesis, molecular modeling and anti-cancer activity against pancreatic cancer cells
Saroj Kumari et al.
MEDCHEMCOMM (2017)
RTN1-C mediates cerebral ischemia/reperfusion injury via ER stress and mitochondria-associated apoptosis pathways
Lingli Gong et al.
CELL DEATH & DISEASE (2017)
Synthesis and anticancer activity of novel quinazolinone-based rhodanines
Sherihan El-Sayed et al.
CHEMISTRY CENTRAL JOURNAL (2017)
Synthesis, antitumor and antimicrobial activity of some new 6-methyl-3-phenyl-4(3H)-quinazolinone analogues: in silico studies
Amer M. Alanazi et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2016)
Design, synthesis and antitumor activity of novel pyrazolo[3,4-d]pyrimidine derivatives as EGFR-TK inhibitors
Mohamed A. Abdelgawad et al.
BIOORGANIC CHEMISTRY (2016)
The Halogen Bond
Gabriella Cavallo et al.
CHEMICAL REVIEWS (2016)
Review on EGFR Inhibitors: Critical Updates
Davinder Singh et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2016)
Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer
Haijun Zhang
DRUG DESIGN DEVELOPMENT AND THERAPY (2016)
The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
Matthew J. Niederst et al.
CLINICAL CANCER RESEARCH (2015)
EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
Dalia Ercan et al.
CLINICAL CANCER RESEARCH (2015)
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
Kenneth S. Thress et al.
NATURE MEDICINE (2015)
Caffeic acid phenethyl ester synergistically enhances docetaxel and paclitaxel cytotoxicity in prostate cancer cells
Mai F. Tolba et al.
IUBMB LIFE (2013)
DFT and MP2 study of low barrier proton transfer in hydrazide schiff base tautomers via water bridges and in the gas
Hossein Tavakol et al.
JOURNAL OF MOLECULAR MODELING (2013)
Novel 4(3H)-quinazolinone analogs: synthesis and anticonvulsant activity
Adel S. El-Azab et al.
MEDICINAL CHEMISTRY RESEARCH (2013)
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Vincent A. Miller et al.
LANCET ONCOLOGY (2012)
Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non-Small-Cell Lung Cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A New Convenient Synthesis of 2,4-Disubstituted-1,2,4-triazolo[1,5-a]quinazolin-5(4H)-ones
Ahmad S. Shawali et al.
JOURNAL OF HETEROCYCLIC CHEMISTRY (2008)
Molecular targeted therapies in breast cancer: Where are we now?
Christian Widakowich et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2007)
The NCI60 human tumour cell line anticancer drug screen
Robert H. Shoemaker
NATURE REVIEWS CANCER (2006)
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
EL Kwak et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Neutron spin interference visibility in tunneling transmission through magnetic resonators
A Utsuro
PHYSICA B-CONDENSED MATTER (2005)
Review of epidermal growth factor receptor biology
RS Herbst
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor
J Stamos et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa® (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo
I Naruse et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
分享论文
